来自官方财务报表的收入、利润与现金流历史。
IDEXX Laboratories, Inc. 为美国和国际上的伴侣动物兽医、家畜和家禽、乳制品和水测试行业开发、制造和分销产品。它通过三个部门运营：伴侣动物集团；水质产品；以及畜牧业、家禽业和乳制品业。该公司提供即时诊断解决方案、血液和尿液化学、血液学、免疫分析、尿液分析、细胞学/形态学和凝血分析仪；和 SNAP 快速检测试剂盒。它还为兽医提供商业参考实验室诊断和咨询服务；兽医咨询、远程医疗和咨询服务，包括放射学、牙科放射学、心脏病学、内科和超声咨询； Colilert、Colilert-18 和 Colisure 测试，检测水中是否存在总大肠菌群和大肠杆菌； Enterolert、Pseudalert、Filta-Max 和 Filta-Max xpress、Legiolert、Quanti-Tray 产品和 Tecta 系统仪器； UV Viewer Plus，一个紫外线灯柜，有助于对基于荧光的水测试进行视觉解释；以及为独立兽医诊所和企业集团提供兽医软件和服务。此外，该公司还提供诊断测试、服务和相关仪器来管理牲畜和家禽的健康状况；人类医学诊断产品和服务； VetConnect PLUS 是一种基于云的技术，使兽医能够访问和分析患者，并运营 VetLab Station。它通过营销、客户服务、销售和技术服务团队以及独立分销商和其他经销商来营销其产品。
机器翻译
| 利润表 | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 总收入 | $4.6B | $4.3B | $3.9B | $3.7B | $3.4B | $3.2B | $2.7B | $2.4B | $2.2B | $2.0B | $1.8B | $1.6B | $1.5B | $1.4B | $1.3B | $1.2B | $1.1B | $1.0B | $1.0B | $923M | $739M |
| 毛利 | $2.8B | $2.7B | $2.4B | $2.2B | $2.0B | $1.9B | $1.6B | $1.4B | $1.2B | $1.1B | $975M | $890M | $816M | $756M | $699M | $647M | $579M | $526M | $530M | $464M | $380M |
| 毛利率% | 62.5% | 61.8% | 61.0% | 59.8% | 59.5% | 58.8% | 58.0% | 56.7% | 56.1% | 55.7% | 54.9% | 55.6% | 54.9% | 54.9% | 54.1% | 53.0% | 52.4% | 51.0% | 51.7% | 50.2% | 51.3% |
| 营业利润（EBIT） | $1.5B | $1.4B | $1.1B | $1.1B | $899M | $932M | $695M | $553M | $491M | $413M | $350M | $300M | $260M | $267M | $263M | $236M | $204M | $176M | $172M | $136M | $128M |
| 营业利润率% | 32.0% | 31.6% | 28.9% | 30.0% | 26.7% | 29.0% | 25.7% | 23.0% | 22.2% | 21.0% | 19.7% | 18.7% | 17.5% | 19.4% | 20.3% | 19.4% | 18.5% | 17.1% | 16.8% | 14.8% | 17.3% |
| 净利 | $1.1B | $1.1B | $888M | $845M | $679M | $745M | $582M | $428M | $377M | $263M | $222M | $192M | $182M | $188M | $178M | $162M | $141M | $122M | $116M | $94M | $94M |
| 净利润率 % | 25.0% | 24.6% | 22.8% | 23.1% | 20.2% | 23.2% | 21.5% | 17.8% | 17.0% | 13.4% | 12.5% | 12.0% | 12.2% | 13.6% | 13.8% | 13.3% | 12.8% | 11.8% | 11.3% | 10.2% | 12.7% |
| EBITDA | $1.6B | $1.5B | $1.3B | $1.1B | $1.0B | $1.0B | $791M | $641M | $575M | $496M | $428M | $370M | $319M | $321M | $315M | $284M | $250M | $226M | $221M | $177M | $158M |
| 每股收益（EPS） | $14.13 | $13.13 | $10.69 | $10.06 | $8.03 | $8.60 | $6.71 | $4.89 | $4.26 | $2.94 | $2.44 | $2.05 | $1.79 | $1.74 | $1.59 | $1.39 | $1.19 | $1.01 | $0.93 | $0.73 | $0.71 |
| 已发行股数 (M) | 81M | 81M | 83M | 84M | 85M | 87M | 87M | 88M | 88M | 90M | 91M | 94M | 102M | 108M | 112M | 116M | 119M | 121M | 124M | 129M | 132M |
来源：公司公开报告（SEC）。在依赖任何数字前请核对 SEC EDGAR。
资产负债表、现金流、季度数据与完整财务比率见 IDXX 交互式查看器。 /companies/us/IDXX
本网站信息仅用于教育与参考，不构成投资建议。不发布目标价或买卖建议。
About TickerBase · Data methodology & sources · Privacy · Terms